Swedish Orphan Biovitrum trades up after launch of rare cap increase
GlobalCapital, is part of the Delinian Group, DELINIAN (GLOBALCAPITAL) LIMITED, 4 Bouverie Street, London, EC4Y 8AX, Registered in England & Wales, Company number 15236213
Copyright © DELINIAN (GLOBALCAPITAL) LIMITED and its affiliated companies 2024

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement
Cookies Settings
EquityFollow-ons and Rights issues

Swedish Orphan Biovitrum trades up after launch of rare cap increase

Victoria Thiele
August 23, 2023 09:26 AM
Sobi at Campus Solna, Stockholm, Sweden. Swedish Orphan Biovitrum AB is an international biopharmaceutical company dedicated to treatments in the areas of haematology, immunology and specialty care, based in Stockholm, Sweden.

Sobi plans to repay debt from an acquisition through a non-underwritten rights issue

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Request a Free Trial or Login

Topics

Follow-ons and Rights issuesBank of AmericaDanske BankSwedenSwedish kronaEquity
VT
Victoria Thiele
Senior Reporter - CLOs
Contact
Gift this article